Zevra Therapeutics, Inc. (ZVRA)
(Delayed Data from NSDQ)
$6.99 USD
+0.21 (3.10%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $6.99 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth A Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ZVRA 6.99 +0.21(3.10%)
Will ZVRA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ZVRA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ZVRA
Zevra Therapeutics (ZVRA) Reports Q2 Loss, Tops Revenue Estimates
Journey Medical Corporation (DERM) Reports Q2 Loss, Tops Revenue Estimates
ZVRA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Century Therapeutics, Inc. (IPSC) Reports Q2 Loss, Tops Revenue Estimates
Earnings Preview: Zevra Therapeutics (ZVRA) Q2 Earnings Expected to Decline
Zevra (ZVRA) Rises on Update on Niemann-Pick Disease Type C Drug
Other News for ZVRA
Zevra Therapeutics reports Q2 results
Zevra Therapeutics (ZVRA) Receives a Buy from Roth MKM
Zevra Therapeutics: Q2 Earnings Snapshot
Zevra Therapeutics Reports Second Quarter 2024 Financial Results and Corporate Highlights
Zevra Therapeutics Inc options imply 8.4% move in share price post-earnings